Introduction

Malignant diseases are major health problems in humans, as well as in the area of veterinary medicine. Although pets and owners share several environmental risks, the development and maturation of malignant tumors in veterinary medicine has been less well studied compared to its human counterpart. Hence, there is a high need for new therapeutic approaches in veterinary oncology.

Authors' Affiliations: 1Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna; 2Centre for Physiology and Pharmacology, Medical University of Vienna; 3Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine Vienna; 4Department for Companion Animals and Horses, University of Veterinary Medicine Vienna; 5Department of Applied Life Sciences, University of Applied Sciences, FH Campus Wien; 6Department of Biotechnology, VIBT-BOKU, University of Natural Resources and Life Sciences, Vienna, Austria; 7Department of Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna; 8Institute of Biochemistry and Molecular Biology, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna; 9Department of Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-51200; Fax: 43-1-40400-61880; E-mail: erika.jensen-jarolim@meduniwien.ac.at

Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

J. Singer and J. Fazekas contributed equally to this work.

Corresponding Author: Erika Jensen-Jarolim, Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, and Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-51200; Fax: 43-1-40400-61880; E-mail: erika.jensen-jarolim@meduniwien.ac.at.

doi: 10.1158/1535-7163.MCT-13-0288

©2014 American Association for Cancer Research.

Large Molecule Therapeutics

Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients

Josef Singer1,3, Judit Fazekas1,3,5, Wei Wang7, Marlene Weichselbaumer1,3, Mirosława Matz1, Alexander Mader6, Willibald Steinfellner6, Sarah Meitz1,3, Diana Mechcheriakova1, Yuri Sobanov1, Michael Willmann4, Thomas Stockner2, Edzard Spillner8, Renate Kunert6, and Erika Jensen-Jarolim1,3

Abstract

Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the anti-EGFR antibody cetuximab in human clinical oncology, we present here a "caninized" version of this antibody, can225IgG, for comparative oncology studies. Variable region genes of 225, the murine precursor of cetuximab, were fused with canine constant heavy gamma and kappa chain genes, respectively, and transfected into Chinese hamster ovary (CHO) DUKX-B11 cells. Of note, 480 clones were screened and the best clones were selected according to productivity and highest specificity in EGFR-coated ELISA. Upon purification with Protein G, the recombinant cetuximab-like canine IgG was tested for integrity, correct assembly, and functionality. Specific binding to the surface of EGFR-overexpressing cells was assessed by flow cytometry and immunofluorescence; moreover, binding to canine mammary tissue was demonstrated by immunohistochemistry. In cell viability and proliferation assays, incubation with can225IgG led to significant tumor cell growth inhibition. Moreover, this antibody mediated significant tumor cell killing via phagocytosis in vitro. We thus present here, for the first time, the generation of a canine IgG antibody and its hypothetical structure. On the basis of its cetuximab-like binding site, on the one hand, and the expression of a 91% homologous EGFR molecule in canine cancer, on the other hand, this antibody may be a promising research compound to establish passive immunotherapy in dog patients with cancer. Mol Cancer Ther; 13(7); 1777–90. ©2014 AACR.
structural homologs in dogs. More specifically, even the relevant epitopes for targeting with cetuximab and trastuzumab are conserved and lead upon targeting to similar biologic events in vitro (11). The growth-inhibitory effect of EGFR and HER2 targeting is due to the silencing of important signaling pathways [PI3K, Ras–Raf (MAPK), JNK, and PLCγ] of growth factors [EGF; ref. 12; and transforming growth factor-α (TGFα); refs. 13–15]. Signaling via EGFR mediates characteristic features of malignancy, such as higher proliferation, but is also associated with higher genomic instability and hormone therapy resistance resulting in poorer overall prognosis in clinics (16).

Both cetuximab and trastuzumab attract immune effector cells to the site of the tumor and elicit tumor cell death via antibody-dependent cell-mediated phagocytosis (ADCP) or antibody-dependent cell-mediated cytotoxicity (ADCC; refs. 17–19). Growth signal inhibition, as well as immune cell-mediated tumor cell death, contribute to high efficacy of cetuximab and trastuzumab in clinical use and lead to clear benefits for patients with advanced colorectal carcinoma with wild-type KRAS status in case of cetuximab treatment (20, 21), as well as longer progression-free and overall survival in patients with metastatic breast cancer with trastuzumab treatment, respectively (22).

As most clinically applied monoclonal antibodies were originally generated in mice, their murine constant regions had to be replaced by human ones (“chimerization”) to avoid immunogenicity and rendering them fully functional. One step further, when only the murine complementarity-determining region (CDR) is grafted into the framework of a consensus human IgG, a “humanized” antibody, such as trastuzumab, results, which is even less immunogenic (23). In the case of cetuximab, chimerization of its mouse precursor antibody “225” (24) led to a 5-fold higher relative affinity toward EGFR as a positive “side effect” and higher biologic efficacy in a human tumor xenograft model (25).

Consequently, the “canizination” of monoclonal antibodies must take place when approaching canine patients with cancer (see the schematic in Fig. 1). Antibodies against oncogenic proteins can act as either tumor promoting (e.g., via cross-linking growth factor receptors and thereby activating the receptors) or tumor inhibiting (e.g., via interference of binding of growth factors), depending on their epitope specificity (26, 27). For 225, it could be demonstrated that upon binding of the antibody to EGFR, EGF-mediated growth signals are inhibited, and the chimerized cetuximab proved to be highly efficacious in clinical trials and clinical use (28). Thus, it was of eminent importance for this study to use the specificity of this successfully applied antibody.

In addition to the growth-inhibitory action due to growth signal deprivation (11), a canizinated cetuximab-like “225 IgG” antibody would lead to the attraction of immune effector cells toward the site of the malignancy. Several studies reported cytotoxic activity of macrophages against canine osteosarcoma (29), melanoma (30), or lymphoma (31), as well as cytotoxic activity of canine natural killer (NK) cells against leukemia blasts (32), two immune effector cell populations, which express Fcγ receptors. Moreover, monocytes, which are known to have tumoricidal properties in humans, could be recruited into tumors (33–35); similarly, neutrophilic granulocytes could also exert ADCC against malignant cells (36). Furthermore, it could be demonstrated that cross-presentation of tumor-associated antigens via Fc receptors on dendritic cells could lead to activation of tumor-reactive T cells and subsequent tumor regression (17).

In summary, we propose the generated canine anti-EGFR IgG to be a potentially highly effective immunotherapeutical tool for clinical veterinary oncology. This antibody could serve as a candidate-research molecule to establish passive immunotherapy for canine patients with cancer as well as a useful tool for proof-of-concept studies in comparative oncology settings. Pharmacokinetic, pharmacodynamic, and pharmacovigilance data of clinical trials in dog patients with cancer will render in return important information for a large number of researchers working on the ErbB-1/EGFR for human anticancer therapy.

Materials and Methods

Cells, monoclonal antibodies, and recombinant proteins

The Chinese hamster (Cricetulus griseus) ovary cell line, Chinese hamster ovary (CHO) DUKX-B11, was purchased from the American Type Culture Collection (ATCC; Cat. No. CRL-9096) and cultivated in Pro CHO 5 Medium (Lonza Group AG) supplemented with Phenol Red (15 mg/L), 0.5 mg/mL Geneticin (G418), 4 mmol/L L-glutamine, and methotrexate (0.038 μmol/L). CHO DUKX-B11 cells were cultivated under serum-free conditions to ensure that they grow in suspension and that an easier purification of IgG upon large-scale production is allowed. Canine (Canis lupus familiaris) mammary carcinoma cell lines P114 and Sh1b were a kind gift of Dr. Gerard Rutte (Department of Clinic Science and Companion Animals, University of Utrecht, Utrecht, the Netherlands). Both cell lines were maintained in DMEM/F12 supplemented with 10% fetal calf serum (FCS), 2 mmol/L L-glutamine, and 10 μg/mL gentamicin sulfate.

Canine (Canis lupus familiaris) cell lines CF33 and CF41, derived from carcinoma of the mammary gland, were obtained from ATCC (Cat. No. CRL-6227 for CF33 and CRL-6232 for CF41) and cultivated in DMEM supplemented with 10% FCS, 2 mmol/L L-glutamine, penicillin (100 U/mL), and streptomycin (100 μg/mL).

The canine cell line TLM1 was used as an EGFR-negative model cell. This oral malignant melanoma cell line (37) was kindly provided by Jaime F. Modiano (Masonic Cancer Center, University of Minnesota, Minneapolis, MN) and kept in DMEM, 10% FCS, 2 mmol/L L-glutamine, penicillin (100 U/mL), and streptomycin (100 μg/mL).
The human (*Homo sapiens*) EGFR-overexpressing cell line A431, derived from an epidermoid carcinoma, and HT29, colorectal adenocarcinoma cells, were purchased from ATCC (Cat. No. CRL-1555 for A431 and HTB-38 for HT29). A431 cells were allowed to grow in DMEM supplemented with 10% FCS, penicillin (100 U/mL), and streptomycin (100 μg/mL). HT29 cells were maintained in RPMI-1640 medium, augmented with 10% FCS, 2 mmol/L L-glutamine, and 10 μg/mL gentamicin sulfate.

The human mammary carcinoma cell line BT474 was a kind gift of Prof. Dr. Thomas Grunt (Institute for Cancer Research, Medical University of Vienna, Vienna, Austria) and was kept in α-MEM (Minimum Essential Medium) supplemented with 10% FCS, 2 mmol/L L-glutamine, penicillin (100 U/mL), and streptomycin (100 μg/mL). All cells were kept at 37°C in a humidified atmosphere of 5% CO₂.

The human cell lines BT474 and A431 were authenticated by single-nucleotide polymorphism (SNP) profiling (Multiplexion GmbH) and HT29 by short tandem repeat (STR) profiling (DDC Medical); non-human cell lines were not authenticated.

Blood samples from dogs, in the course of diagnostic work-ups or routine check-ups at the oncology unit at the Small Animal Hospital, University of Veterinary Medicine Vienna (Vienna, Austria), were used for peripheral blood mononuclear cell (PBMC) purification. The study was discussed and approved by the Institutional Ethics Committee in accordance with Good Scientific Practice (GSP) guidelines and national legislation.

Cetuximab (Erbitux), a chimeric IgG1 anti-EGFR monoclonal antibody, was acquired from Merck KGaA, and trastuzumab (Herceptin), a humanized IgG1 monoclonal anti-HER2 antibody, was obtained from Roche. Rituximab (MabThera), a chimeric IgG1 anti-CD20 monoclonal antibody, served as an isotype control (Roche). Dog IgG (mixed breed, affinity purified from serum, produced by Innovative Research, and distributed by Dunn Laborteknik GmbH) was used as a canine antibody isotype control (canine IgG standard).

Recombinant human extracellular domain (ECD)-EGFR was purchased from ACROBiosystems. Recombinant human ECD-HER2 was purified via its His-tag from supernatants of transfected Lec-1 cells, which were a kind gift of Prof. Daniel Leahy (Johns Hopkins University School of Medicine, Baltimore, MD). Bovine serum albumin (BSA) served as an additional negative control protein and was obtained from Sigma-Aldrich.

Cloning of canine Fc regions from PBMCs, cetuximab-variable regions from 225, and vector design

Using real-time PCR, four canine IgG heavy chain genes (IgG A, B, C, and D) were obtained from normal canine PBMC cDNA. Of these subclasses, IgGC was chosen for all consecutive cloning approaches.
Oligonucleotide primers for obtaining the IgGC constant region sequence were gatcgcagggcctcaccaggccc (forward sequence containing an XhoI site) and gatgggccacggcctactcttctcag (reverse sequence containing an SfiI site). In addition, primers gatggccgacggcctccacttattgttccaaccatct (forward sequence with an SgsI site included) and gatctcgtccttcctctcctgtcaggtgcagctgaagcagtcag and gatctcgacgagtagctgctgactcagtctc and gatcggcgcgcctttcagctccagcttggt- amplifying an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site.

The cetuximab heavy chain variable region was amplified from cDNA of a muslin precursor hybridoma cell line 225 (ATCC no. HB-8508), using the primers gatcatttaaatgtgtccagtgtcaggtgcagctgaagcagtcag and gatctcgacgagtagctgctgactcagtctc and gatcggcgcgcctttcagctccagcttggt- using an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site. The variable light chain region was amplified using Clustal X (43). The sequence conservation scores, as defined by Clustal, were then mapped onto the model of can225IgG antibody.

The cetuximab heavy chain variable region was amplified from cDNA of a muslin precursor hybridoma cell line 225 (ATCC no. HB-8508), using the primers gatcatttaaatgtgtccagtgtcaggtgcagctgaagcagtcag and gatctcgacgagtagctgctgactcagtctc and gatcggcgcgcctttcagctccagcttggt- using an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site and incorporating an SfiI site. The variable light chain region was amplified using Clustal X (43). The sequence conservation scores, as defined by Clustal, were then mapped onto the model of can225IgG antibody.

**Production of recombinant antibodies**

Purified plasmids were transfected into CHO DUKX-B11 cells using polyethyleneimine (PEI; 25-kD linear, Polysciences Inc.) as transfection agent and seeded onto 96-well cell culture plates to generate 480 different clones in total. Clones of interest were selected by G418 and increasing concentrations of methotrexate (methotrexate hydrate; Sigma-Aldrich) and screened by ELISA for antibody production yields as well as for specificity against EGFR.

**ELISA**

For productivity screening of the clones, ELISA plates (Immuno MaxiSorp; Nunc) were coated overnight at 4°C with 1 μg/mL rabbit anti-dog IgG (Fc; Acris Antibodies GmbH) or 0.5 μg/mL goat anti-dog light chain antibodies (Bethyl Laboratories, Inc.) in carbonate buffer, respectively. After a blocking step, cell culture supernatants of clones of interest were diluted at 1:5 in phosphate-buffered saline (PBS), 0.05% Tween20 (PBST) + 1% BSA (Sigma-Aldrich). Following application, the plates were incubated for 1 hour at room temperature. Rabbit anti-dog IgG horseradish peroxidase (HRP; Jackson ImmunoResearch Europe Ltd.) was applied at a 1:5,000 dilution in PBST + 1% BSA, again for 1 hour at room temperature. Between all incubation steps, plates were washed three times with 200 μL PBST. For detection, 3,3',5,5'-tetramethylbenzidine (TMB; BD Biosciences) was added, and after stopping the reaction with 1.8 mol/L H2SO4, the optical density (OD) absorbencies of the wells were measured at 450 nm (with a reference at 620 nm) with a multiwell plate reader (Infinite M200 PRO; Tecan Group AG).

To test the secreted antibodies for their selectivity toward EGFR, cell culture supernatants of clones displaying the highest yields of total IgG were examined in EGFR-specific ELISA as well. Immunoassay plates (Immuno MaxiSorp; Nunc) were coated overnight at 4°C with 0.5 μg/mL recombinant human EGFR (Acro Biosystems) in carbonate buffer. To prevent unspecific binding, blocking was carried out for 2 hours at room temperature with Tris-buffered saline (TBS), 0.05% Tween20 (TBST) + 1% dried milk powder (DMP). Cell culture supernatants were diluted at 1:5 in TBST + 0.1% DMP. Control antibodies cetuximab (positive) and trastuzumab (serving as negative control) were applied in four serial dilution steps (1:2), starting with 0.5 μg/mL, again in TBST + 0.1% DMP. Plates were incubated for 2 hours at room temperature. Rabbit anti-dog IgG HRP (1:5,000) or anti-human IgG HRP, at a 1:8,000 dilution, were applied to the respective wells in TBST + 0.1% DMP, following an incubation period of 1 hour at room temperature. Between each step, plates were washed three times with 200 μL TBST. HRP signal was again detected with TMB substrate.

**PAGE and immunoblotting**

For protein gel electrophoresis, semi‐cast 10% SDS–acylamide gels were used.
Semi-dry blotting was performed according to the standard blotting protocols, using nitrocellulose membranes. Blocking was carried out by incubation in TBS, 0.1% Tween20 (TBST; 50 mmol/L, 150 mmol/L NaCl; pH 7.5) + 5% DMP for 2 hours at room temperature. For detection of the canine heavy gamma Fc chain, HRP-labeled rabbit anti-dog IgG (Fc) antibodies (Jackson ImmunoResearch Europe Ltd.) were used at a 1:5,000 dilution. After washing three times with TBST for 10 minutes, binding of the HRP-conjugated antibodies was detected by incubation with ECL BD OptiEIA substrate (BD Biosciences), using a VersaDoc Imaging System (Bio-Rad Laboratories, Inc.).

For detection of the canine kappa light chain, goat anti-dog light chain (Bethyl Laboratories, Inc.) and rabbit anti-goat IgG alkaline phosphatase (AP; Sigma-Aldrich) antibodies were consecutively used at a 1:2,000 dilution. Binding of AP-labeled antibodies was detected using nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate, toluidine salt solution (NBT/BCIP; Roche Diagnostics GmbH).

**Purification of recombinant proteins**
The can225IgG cell culture supernatant of the chosen clone 3A3 (subclone 3A3/14E1, respectively) was dialedyzed before purification in 20 mmol/L sodium phosphate buffer (pH 7.0) overnight at 4°C under gentle stirring. Dialysis buffer was exchanged at least twice. For purification of the dialedyzed supernatant, the Fast Protein Liquid Chromatography system (FPLC; AKTA; GE Healthcare Europe GmbH) was applied, using either a 1 ml HiTrap Protein A HP column (GE Healthcare), a 1 ml recombinant Protein A column (UNOsphere SUPrA; Bio-Rad Laboratories, Inc.), or a 5 ml HiTrap Protein A HP column (GE Healthcare). Furthermore, several small-scale purification attempts using Protein G Sepharose 4 Fast Flow beads (GE Healthcare) were performed before FPLC purification with HiTrap Protein G HP 5 ml column (GE Healthcare) was established, with a flow rate of 5 ml/min.  To elute bound can225IgG, 0.1 mol/L Glycine–HCl buffer (pH 2.7) was applied. Upon elution, samples were immediately neutralized with 1 mol/L Tris–HCl (pH 9.0).

**Circular dichroism spectroscopy**
Circular dichroism (CD) spectroscopic analyses were performed as described previously (44, 45). In short, dog antibody samples (c = 100 μg/mL ddH2O) were assessed at a J-715 spectropolarimeter (Jasco), using a 1-mm path-length quartz cuvette (Hellma) equilibrated at 20°C. Scan speed for spectra measurement was 50 nm/min at a 0.2-nm resolution. The average of five scans was taken as result after subtraction of the baseline spectrum and is shown as mean residue ellipticity (θ) at the respective wavelengths.

**Flow cytometry**
To assess specific binding of the generated can225IgG to natural canine EGFR expressed on the surface of canine mammary carcinoma cell lines, flow cytometric analyses were performed. Cells (300,000/tube) were washed three times with FACS buffer (PBS + 2% normal goat serum). Afterward, cells were incubated for 30 minutes at 4°C in the dark with 200 μL of 10 μg/mL can225IgG as primary antibody and 200 μL of 10 μg/mL canine IgG standard as isotype control, in FACS staining buffer (PBS +2% normal goat serum +1% normal rabbit serum). Upon washing with FACS buffer, cells were incubated with 200 μL of 10 μg/mL rabbit anti-dog IgG FITC antibodies (Jackson ImmunoResearch Europe Ltd.) for 30 minutes at 4°C. After another washing step, cells were analyzed using the dual-laser FACSCalibur (BD Biosciences).

To evaluate binding properties of can225IgG to dog monocytes, PBMCs were isolated from canine patients with carcinoma using Ficoll-Paque separation (GE Healthcare Europe GmbH). PBMCs were incubated with 200 μL of 10 μg/mL can225IgG as primary antibody and 200 μL of 10 μg/mL canine IgG standard as positive control, respectively. Subsequently, cells were incubated with 200 μL of 10 μg/mL anti-dog IgG FITC and mouse anti-human CD14 phycoerythrin (PE; clone TUK4; Life Technologies), which is cross-reactive to dog CD14 to identify monocyte cells. Analysis was again carried out using a dual-laser FACSCalibur (BD Biosciences). Histograms of FACS data were plotted with the FlowJo 10.0.6 software (TreeStar, Inc.).

**Viability assays**
To assess the tumor-inhibitory properties of the recombinant can225IgG, tetrazolium-based cell viability assays were performed according to the manufacturer’s instructions (EZ4U The 4th Generation Non Radioactive Cell Proliferation & Cytotoxicity Assay Kit; Biomedica). A431 cells were seeded at a density of 3 × 10⁴ per well in a 96-well plate (round-bottomed). After overnight incubation for proper adhesion to the plate, cells were treated with either 5 μg/mL can225IgG, 5 μg/mL cetuximab, 5 μg/mL dog IgG standard, or 5 μg/mL rituximab for 48 hours. Subsequently, tetrazolium substrate was added, and after another 3 hours of incubation, OD was measured at 450 nm with 620 nm as the reference wavelength.

**Proliferation assays**
To directly measure DNA replication, BrdU Proliferation assays (Roche) were performed. BrdU (bromodeoxyuridine) is a nonradioactive compound, which is incorporated into the genomic DNA of proliferating cells during DNA synthesis. EGFR-expressing canine cell lines P114 and Sh1b, as well as the negative control cell line TLM1, were seeded onto 96-well cell culture plates at a density of 3 × 10⁴ per well in a 96-well plate (round-bottomed). After overnight incubation for proper adhesion to the plate, cells were treated with either 5 μg/mL can225IgG, 5 μg/mL cetuximab, 5 μg/mL dog IgG standard, or 5 μg/mL rituximab for 24 hours before labeling with BrdU. After a labeling period of 4 hours, incorporated BrdU was detected with an HRP-conjugated anti-BrdU antibody. Bound antibodies were detected with TMB, and color reaction was measured at 450 nm in an ELISA reader,
with 630 nm as a reference value (Infinite M200 PRO; Tecan Group AG).

ADCC/ADCP assay

To determine the levels of immune cell-mediated tumor cell killing via ADCC and ADCP, a three-color flow cytometric assay (46) was adapted to the canine system. EGFR-expressing canine P114 cells were stained with CFDA [Spiro(isobenzofuran-1(3H),9’-(9H)xanthene)-5-carboxylic acid, 3’,6’-bis(acetyloxy)-oxo-, (acetyloxy) methyl ester; Invitrogen, Life Technologies] and served as target cells. PBMCs, purified from canine patients with cancer, served as effector cells. Effector (E) and target (T) cells were coincubated at a ratio of 3:1 (300,000 E:100,000 T; total volume = 400 μL) in the presence or absence of can225IgG (c = 2.5 μg/mL). After 2.5 hours of incubation, the killing assay was stopped by adding ice-cold FACS buffer. Effector cells were labeled with anti-CD14 PE (clone TUK4; Life Technologies). After another 30 minutes of incubation at 4°C and subsequent washing, dead cells were labeled with 7-amino-actinomycin D (7-AAD; eBioscience) for 15 minutes at 4°C. After a final washing step, cells were resuspended in 200 μL FACS buffer and analyzed on a dual-laser FACSCalibur (BD Biosciences).

Data handling and statistical analysis

Flow cytometric experiments of receptor binding and competitive binding were repeated at least three times, and histograms display one representative example. In ADCC/ADCP assays, 3 canine patients with cancer were investigated, and three samples were measured from each dog. Statistical analyses were performed again by using the two-sided t test. All statistic calculations were performed using the GraphPad Prism 4 software (GraphPad).

Results

Construction and modeling of can225IgG

Figure 2 shows the topography of the constructed can225IgG antibody in comparison with human cetuximab IgG. Thus, the variable region and EGFR-binding site was grafted on the canine IgG backbone (Supplementary Table S1). Sequence comparisons suggested an approximately 60% homology across heavy and light chains. On the basis of this information, we approached in silico the hypothetical structure of the canine cetuximab counterpart. The information was collected by assembling cetuximab variable regions from PDB (ID: 1YY8) with amino acid translations of the constant canine heavy chain region C gene AAL33030.1/AF354266.1, and the canine constant kappa light chain region gene, XP_532962.3 (Fig. 2A). Upon closer investigation of conserved structures between human and canine immunoglobulin sequences, “conservation mapping” could be performed on the modeled antibody. As can be seen in Fig. 2B, regions with identical amino acids are depicted in blue, whereas amino acid changes are indicated in various shades of green, depending on the grade of discrepancy of amino acids. As the variable regions of both heavy and light chains were taken from the original cetuximab sequence, no differences can be observed in this part of the molecule. Regions with highest amino acid variability include the hinge region and parts of the constant regions that do not bind to Fcγ receptors.

Productivity and specificity screening of transfected clones in ELISA

Plasmids for heavy and light chains of can225IgG were constructed on the basis of the above information and transfected into CHO DUKX-B11 cells. Clones with highest production yields (Fig. 3A) were screened for specificity in ELISA coated with the ECD of human recombinant EGFR, and recombinant human HER2 for control purposes. Original cetuximab antibody was used as a positive control. All tested clones produced IgG highly specific to EGFR, whereas none of it bound to HER2, a closely related and highly homologous molecule that does not display the 225 epitope (Fig. 3B).
Generation of a Canine Anti-EGFR Antibody

Integrity testing of secreted antibodies in cell culture supernatants

Seven highly productive and specific clones were selected for further analysis. The integrity of the generated antibodies was proven by Western blot analysis, detecting the canine heavy gamma and kappa light chain. The signals were observed at the correct molecular size in comparison with canine IgG standard (canine IgG STD), and no unassembled single heavy chains were detectable (Fig. 3C). In parallel, the detection of light chain displayed sharp bands at the same molecular size as that of purified standard canine IgG, and again no unassembled single light chains were traceable (Fig. 3D). Therefore, each selected clone produced intact, correctly assembled antibodies.

Purification of recombinant proteins

Having displayed high productivity, specific binding to recombinant EGFR, as well as intact and correct assembly of cetuximab-like can225IgG, clone 3A3 was subjected to amplification and supernatants to purification via Protein A affinity chromatography. As can be seen from Supplementary Fig. S1A, unexpectedly and despite published work (47–49), can225IgG did not bind to Protein A.

In contrast, substantial binding to Protein G Sepharose beads could be observed (Supplementary Fig. S1B), resulting in proper purification of the recombinant can225IgG antibodies from cell culture supernatant (Supplementary Fig. S2). Thus, FPLC in combination with Protein G columns was chosen as the method for large-scale purification.

Integrity testing of purified antibodies

As an additional step of quality control, we assessed the correct folding of the purified antibodies in CD spectroscopy. The secondary structures of can225IgG cannot be detected with purified dog IgG standard (canine IgG STD), and no unassembled single heavy chains were detectable (Fig. 4). It can, thus, be concluded that due to the four amino acid changes in the 225 epitope (11), there is a difference in the affinity of the newly generated can225IgG toward human and canine EGFR, however, the affinity is still high enough to bind and exert function.

Flow cytometric analysis of can225IgG binding to EGFR-expressing cells

For specificity testing of the generated can225IgG toward natural EGFR on the surface of cells, flow cytometric analyses were performed. EGFR-overexpressing canine mammary carcinoma cells P114 and Sh1b, as well as the established human EGFR-overexpressing model cell lines A431 and HT29, were used (Fig. 4). The newly generated can225IgG specifically stained all four cell lines, depending on the amount of expressed proteins. P114 cells were stained with a shift in median fluorescence intensity (MFI) of 5.86 (4.44 for isotype control to 10.30 for can225IgG). Sh1b cells showed a MFI of 4.67, HT29 of 92.65, and A431 had a MFI of 946.83. In the case of the CF35 and CF41 cells, which express low levels of EGFR (11), specific staining could again be observed (Supplementary Fig. S3A and S3B). The specificity of can225IgG was further affirmed by staining EGFR-negative canine melanoma cells TLM1, rendering only background signal (Supplementary Fig. S3C).

Possible affinity differences of can225IgG binding toward canine and human EGFR were addressed by competitive flow cytometry on canine P114 and human BT474 cells (a human mammary carcinoma cell line that shows similar EGFR expression as the established canine mammary carcinoma cells; see Supplementary Fig. S3D). Supplementary Fig. S4A–S4C displays that A431 cells would not have been applicable for this assay, as their EGFR density is more than 100-fold.

The known affinity of cetuximab binding to human EGFR has a $K_d$ value of 0.39 nmol/L (50). As can be seen from Supplementary Fig. S4D, can225IgG binding to canine cancer cells can be removed by molar excess of soluble human EGFR, whereas this is not possible when can225IgG binds to human cancer cells (Supplementary Fig. S4E). It can, thus, be concluded that due to the four amino acid changes in the 225 epitope (11), there is a difference in the affinity of the newly generated can225IgG toward human and canine EGFR; however, the affinity is still high enough to bind and exert function.

Microscopy

Specific binding of purified can225IgG antibodies was also confirmed by microscopy. Whereas neither canine (Supplementary Fig. S5A, top left) nor human isotype controls (Supplementary Fig. S5A, bottom left) showed any signal, both can225IgG (Supplementary Fig. S5A, top right) and the original antibody cetuximab (Supplementary Fig. S5A, bottom right) displayed strong, membrane-specific staining of A431 cells.

To further investigate the binding properties of can225IgG on malignant tissue, canine mammary carcinoma samples were tested for EGFR expression with the FDA-approved in vitro diagnostic EGFR pharmDx kit. Positive specimens, which show a strong and complete membrane-specific staining (Supplementary Fig. S5B, left), were also used for staining with purified dog IgG standard and can225IgG (Supplementary Methods). The control dog IgG standard did not stain any structures specifically (Supplementary Fig. S5B, middle), whereas incubation with can225IgG resulted in EGFR staining, comparable with the diagnostic kit, though less intense (Supplementary Fig. S5B, right).

Cell viability and proliferation assays

For assessment of the tumor-inhibitory properties of the newly generated can225IgG antibody, cell viability assays with highly EGFR-overexpressing A431 cells were performed (Fig. 5A). After 48 hours of treatment with can225IgG, only 85.80% of viable cells could be detected (compared with untreated A431 cells), whereas incubation with purified dog IgG standard led to normal cell growth (98.79%). Thus, significant growth inhibition could be observed ($P = 0.0002$).
For control purposes, the same experiment was conducted with cetuximab and rituximab, respectively (in same concentrations, 5 \( \mu \)g/mL). Again rituximab, the unspecific isotype control, showed no growth-inhibitory effect (100.53%), whereas treatment with cetuximab led to the expected significant growth inhibition (84.44%; \( P = 0.0001 \)).

In addition to the tetrazolium-based cell viability assays, BrdU incorporation experiments were carried out to measure the direct impact of the newly generated can225 IgG on the proliferation of canine cancer cells. Thus, P114 and Sh1b cells were incubated for 24 hours with can225IgG as well as cetuximab, which served as positive control. As can be seen in Fig. 5B and C, both canine cell lines could be significantly inhibited in their growth by cetuximab and can225IgG (P114: \( P < 0.0001 \) for both antibody-treated groups compared with untreated cells; Sh1b: \( P = 0.002 \) for cetuximab-treated and \( P = 0.0034 \) for can225IgG-treated cells compared with untreated ones). In contrast, treatment of EGFR-negative canine TLM1 cells did not lead to any significant change in proliferation (Fig. 5D).

For control purposes, the same experiment was conducted with cetuximab and rituximab, respectively (in same concentrations, 5 \( \mu \)g/mL). Again rituximab, the unspecific isotype control, showed no growth-inhibitory effect (100.53%), whereas treatment with cetuximab led to the expected significant growth inhibition (84.44%; \( P = 0.0001 \)).

In addition to the tetrazolium-based cell viability assays, BrdU incorporation experiments were carried out to measure the direct impact of the newly generated can225 IgG on the proliferation of canine cancer cells. Thus, P114 and Sh1b cells were incubated for 24 hours with can225IgG as well as cetuximab, which served as positive control. As can be seen in Fig. 5B and C, both canine cell lines could be significantly inhibited in their growth by cetuximab and can225IgG (P114: \( P < 0.0001 \) for both antibody-treated groups compared with untreated cells; Sh1b: \( P = 0.002 \) for cetuximab-treated and \( P = 0.0034 \) for can225IgG-treated cells compared with untreated ones). In contrast, treatment of EGFR-negative canine TLM1 cells did not lead to any significant change in proliferation (Fig. 5D).

For control purposes, the same experiment was conducted with cetuximab and rituximab, respectively (in same concentrations, 5 \( \mu \)g/mL). Again rituximab, the unspecific isotype control, showed no growth-inhibitory effect (100.53%), whereas treatment with cetuximab led to the expected significant growth inhibition (84.44%; \( P = 0.0001 \)).

In addition to the tetrazolium-based cell viability assays, BrdU incorporation experiments were carried out to measure the direct impact of the newly generated can225 IgG on the proliferation of canine cancer cells. Thus, P114 and Sh1b cells were incubated for 24 hours with can225IgG as well as cetuximab, which served as positive control. As can be seen in Fig. 5B and C, both canine cell lines could be significantly inhibited in their growth by cetuximab and can225IgG (P114: \( P < 0.0001 \) for both antibody-treated groups compared with untreated cells; Sh1b: \( P = 0.002 \) for cetuximab-treated and \( P = 0.0034 \) for can225IgG-treated cells compared with untreated ones). In contrast, treatment of EGFR-negative canine TLM1 cells did not lead to any significant change in proliferation (Fig. 5D).
Flow cytometric analysis of can225IgG binding to canine monocytes

Functionality of the newly generated antibody with respect to binding to Fcγ receptors on dog immune cells was tested by flow cytometry. Thus, PBMCs of canine patients with cancer (n = 3) were purified and stained with can225IgG or dog IgG standard as positive control. Monocytes, important effector cells in tumor immunotherapy, were identified by staining with anti-CD14 PE and as shown in Fig. 6A, can225IgG binds to the same extent on monocytes as the purified canine IgG standard.

ADCC/ADCP assays

As one of the major mechanisms of cetuximab is to confer immune-mediated tumor cell death, the newly generated can225IgG was also assessed in this regard. Therefore, a three-color flow cytometric method was applied, which is able to measure ADCC and ADCP simultaneously. Again, EGFR-overexpressing canine mammary carcinoma cells P114 were investigated. A total of 1 x 10^5 cells were coincubated with three times the amount of PBMCs, isolated from dog patients with cancer. After 2.5 hours of incubation in the presence of can225IgG, a significant difference in the level of ADCP could be observed (P = 0.0153; Fig. 6C). For ADCC (Fig. 6B), no significant difference could be displayed.

Discussion

As human and veterinary oncology face similar challenges, such as comparable incidence rates in certain tumor types (51), with studies even reporting higher rates in dogs for mammary cancer in the same geographic area (52), comparative approaches could be highly valuable for both human and veterinary oncology. Recent studies recognized the high similarities between human and canine genes as a result to the unraveling of the canine genome (53). Similar genetic risk factors were identified for humans and dogs contributing to breast cancer development, including BRCA-1 and BRCA-2 (2). In addition, clinical features of the disease, such as metastatic behavior...
Generation of a Canine Anti-EGFR Antibody

Figure 6. Binding of can225IgG to canine monocytes and assessment of immune cell–mediated cancer cell death. A, evaluation of can225IgG binding to Fcγ receptors on mononuclear cells purified from dog patients with cancer. Monocytes (gated as CD14 PE–positive) were stained with anti-dog IgG FITC (gray histogram). Can225IgG (dotted line) as well as canine IgG STD (black line, serving as positive control) are able to bind specifically; ΔMFI for can225IgG = 18.3; ΔMFI for canine IgG STD = 19.3 (p = 0.03; one representative example depicted). B, measurement of ADCC of P114 cells mediated by can225IgG. PBMCs were purified from dog patients with cancer (n = 3) and incubated with P114 cells for 2.5 hours in the presence or absence of can225IgG, which led to no significant change of cytotoxicity levels. C, measurement of ADCP of P114 cells mediated by can225IgG. PBMCs were purified from dog patients with cancer (n = 3) and incubated with P114 cells for 2.5 hours in the presence or absence of can225IgG, which led to a significant increase in phagocytosis of cancer cells (P = 0.0153).

(54) or dissemination into the bone marrow and circulation, have been closely investigated (55). Several tumor-associated antigens, particularly important for targeted therapies in human oncology, could also be identified in canine malignancies, such as CD20 (56), EGFR (57–59), HER2 (60), or VEGF (61). Our group revealed in a previous study that close homologs of EGFR (ErbB-1) and HER2 (ErbB-2) are overexpressed in canine mammary carcinoma lesions; and more importantly, that the relevant epitopes for the clinically applied monoclonal antibodies cetuximab and trastuzumab are highly conserved between the two species (11). Both antibodies are effective in human clinical use (20, 22), but they have as well a tumor-inhibitory potential on canine mammary carcinoma cells in vitro (11).

Thus, targeting of EGFR in veterinary clinical oncology could contribute to new insights into cancer biology, development of resistance mechanisms, or safety and efficacy of targeted therapies of the next generation. By testing new anti-EGFR agents head-to-head in human and canine patients, state-of-the-art therapies could be provided simultaneously for veterinary medicine. This goal is strongly fostered by the comparative oncology trials consortium, founded by the National Cancer Institute (NCI, Bethesda, Maryland) in 2003 (3).

Cetuximab (Erbitux), a monoclonal mouse–human chimeric IgG1 antibody directed against human EGFR (ErbB-1), could serve as a promising lead compound for comparative studies, because its activity is not limited to growth signal inhibition mediated via its Fab region, but it is also able to elicit immune cell–mediated tumor cell death via its Fc regions. 225, the murine precursor of cetuximab, was chimerized leading to higher relative affinity toward EGFR and higher biologic efficacy in in vivo studies with human tumor xenografts (25). Thus, we aimed to similarly generate a “caninized” 225 IgG antibody, termed can225IgG, by applying the same variable regions as 225, but fuse them with canine Fcγ regions (Fig. 1) to exploit the canine cellular effector mechanisms. Therefore, its variable regions were amplified from the cDNA of the hybridoma cell line 225 and reassessed with the published amino acid sequence of the cetuximab-Fab cocrystallized with human EGFR (62). As dogs display four different isotypes of γ-immunoglobulins (IgG A, B, C, and D; ref. 63), specific primers against each subclass were designed and gene sequences were obtained from canine PBMC cDNA. Gamma heavy chain protein of IgGC displayed 67.7% identity to the amino acid sequence of the human IgG1 heavy chain (RCSB pdb-database, No. 3RY6), an isotype long known for mediating cytotoxicity in humans (64) and representing the isotype of almost all FDA-approved monoclonal antibodies (65). Thus, IgGC was chosen for all subsequent cloning steps and for production of the chimeric can225IgG. To match the obtained gamma heavy chain C sequence with published ones, alignment against the published protein sequence AAL35303.1/AF354266.1 (63) was performed. This alignment displayed four amino acid mutations between the two sequences, which could be explained by genetic divergence due to breeding. As a complete analysis of the influence of race and breeding would have exceeded the focus of this study, we decided to use the published sequence from NCBi’s Protein database (National Center for Biotechnology Information, Bethesda, MD). Similarly, the amino acid sequence of the extracted kappa constant region was aligned to XP_532962.3, which resulted in complete accordance. Final sequences were optimized for production in Cricetulus griseus and transfected into CHO...
DUKX-B11 cells. Having established stable-transfected cell lines, clones were screened for productivity (Fig. 3A) and specificity (Fig. 3B).

Supernatants of clones that have undergone positive ELISA screening were again tested by Western blot analysis to determine the biochemical properties of secreted proteins. Figure 3C shows that all selected clones displayed a sharp band at the same molecular mass as control IgG standard, thus representing fully assembled canine immunoglobulins (Fig. 3D). As the positive control IgG comprises kappa and lambda light chains, and the detection antibody is directed against both, the signal intensity of the can225IgG band, comprising only kappa, cannot be compared par for par.

According to the literature, we expected medium-to-strong binding affinity of Protein A to canine IgG (47–49). Thus, purification of the recombinant can225IgG antibodies via Protein A affinity chromatography was our first method of choice, but can225IgG did not bind to recombinant Protein A (Supplementary Fig. S1A). This prompted us to purify via Protein G (66). Supplementary Fig. S1B demonstrates that can225IgG bound to Protein G and could be eluted via a pH shift with 0.1 mol/L glycine (pH 2.5) buffer. Again, SDS–PAGE affirmed the stability and purity of eluted proteins. Purified can225IgG showed the same sharp band as can225IgG in cell culture supernatants before purification, indicating proper refolding after neutralization in Tris–HCl buffer (pH 9.8); Supplementary Fig. S2). Furthermore, still no unassembled heavy or light chains could be detected in the gel.

To confirm the proper folding of can225lgG after the pH drop during purification, CD spectroscopy was performed (Fig. 3E), displaying again comparable results for molecular ellipticity between can225lgG and canine IgG standard.

For closer examination of tertiary structures of the newly generated can225lgG, molecular modeling was applied on the basis of crystallographic structures of human antibodies. Figure 2A displays predicted structures of can225lgG and the assembly of heavy and light chains based on these assumptions. To localize differences, “conservation mapping” was performed, displaying high variability between human and canine molecules, especially in the hinge region of the antibodies (Fig. 2B).

Next, the binding capacity of can225lgG to EGFR was tested by flow cytometric analyses with EGFR-overexpressing human as well as canine carcinoma cell lines. As illustrated in Fig. 4 and Supplementary Fig. S3, can225lgG is capable of detecting EGFR on the surface of cell lines (such as A431, HT29, P114, Sh1b, CF33, and CF41 cells) that have been previously reported to express this receptor; yet, no binding was seen on TLM1 canine melanoma cells (Supplementary Fig. S3C). Also, in immunofluorescence, can225lgG displayed the same membrane-specific staining pattern on A431 cells as that of cetuximab (Supplementary Fig. S5A).

Moreover, binding of can225lgG to EGFR expressed on malignant canine mammary cancer lesions could be demonstrated by immunohistochemistry, again leading to a comparable staining pattern like the FDA-approved diagnostic EGFR pharmDx test (Supplementary Fig. S5B). Different staining intensities of can225lgG and EGFR pharmDx can, at least in part, be explained by a different epitope specificity of 2-18C9, the monoclonal antibody used in the diagnostic kit (2-18C9 binds to the extracellular cysteine-rich region of the molecule spanning domain II proximal to the transmembrane region, whereas 225 has its epitope in domain III of EGFR), as it was also demonstrated previously that distinct antibodies against EGFR lead to different staining intensities in immunohistochemistry (67, 68).

The most important aim of this study was to demonstrate the tumor-inhibitory potential of can225lgG. Indeed, both can225lgG and cetuximab rendered comparable levels of growth inhibition in vitro via growth signal depletion after 24 or 48 hours of incubation, respectively (Fig. 5).

All cellular assays clearly illustrate that can225lgG shows the same or comparable biochemical and functional properties as original cetuximab.

Moreover, we also addressed the immune-mediated tumoricidal effects of can225lgG. Therefore, we proved its capability to bind to Fcγ receptors on canine mononuclear cells (Fig. 6A), which are known as important effector cells in tumor immunotherapy (35). Indeed, coincubated with canine PBMcs, can225lgG was able to mediate significant levels of phagocytosis (ADCP) in canine mammary carcinoma cells (Fig. 6C). Yet, no significant ADC could be recorded (Fig. 6B), possibly due to partially high background cytotoxicity and large variation in the samples caused by a high diversity of the canine patients with respect to age, sex, and breed. However, the observation of an IgG antibody mediating significant amounts of ADCP, but not ADC, in this three-color flow cytometric method was also previously described for trastuzumab and HER2-overexpressing cancer cells in the human setting (18, 69).

In summary, this newly generated “caninized” anti-EGFR antibody seems to be highly specific as well as effective in targeting EGFR-overexpressing canine tumor cells. Its caninization prevents adverse reactions, such as anaphylaxis or serum sickness in treated dogs, making this antibody a safe research lead compound for the first passive immunotherapy approaches in canine patients with cancer.

Disclosure of Potential Conflicts of Interest

E. Spillner has ownership interest in a patent. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: E. Jensen-Jarolim
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc): J. Singer, J. Fazekas, W. Wang, M. Weichselbaumer, A. Mader, S. Meitz, D. Mechthethiakova, M. Willmann, T. Stockner, R. Kunert, E. Jensen-Jarolim

Published OnlineFirst April 22, 2014; DOI: 10.1158/1535-7163.MCT-13-0288

Writing, review, and/or revision of the manuscript: J. Singer, J. Fazekas, M. Weichselbaumer, D. Mechtcheriakova, M. Willmann, T. Stockner, E. Jensen-Jarolim

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W. Steinfellner, Y. Sobanov, R. Kunert

Study supervision: D. Mechtcheriakova, E. Jensen-Jarolim

Other: M. Matz, E. Spillner

Acknowledgments

The authors thank all members of the Jensen-Jarolim laboratory for inspiring discussions and support. They also thank Prof. Wb for help in detection of EGFR in canine cancer samples, Judith Frei for assisting in ADCC/ADCP assays, and Michael Schranz for excellent advice in amplifying immunohistochemical signals with tyramide.

Grant Support

This work was supported by grant P23398-B11 (to E. Jensen-Jarolim) of the Austrian Science Fund (FWF) and J. Singer and J. Fazekas were supported by the CCHD PhD program, FWF project W1205-B09 (to E. Jensen-Jarolim).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 22, 2013; revised April 14, 2014; accepted April 14, 2014; published OnlineFirst April 22, 2014.

References


44. Scott MA, Davis JM, Schwartz KA. Staphylococcus protein A binding to canine IgG and IgM. Vet Immunol Immunopathol 1997;59:205–12.


Molecular Cancer Therapeutics

Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients

Josef Singer, Judit Fazekas, Wei Wang, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-13-0288

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2014/04/22/1535-7163.MCT-13-0288.DC1

Cited articles
This article cites 67 articles, 13 of which you can access for free at:
http://mct.aacrjournals.org/content/13/7/1777.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/13/7/1777.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.